INTRODUCTION {#S1}
============

The nature of the immune response in the intestine may require either immunosuppression or controlled inflammation. The suppressive state is dictated by several factors including regulatory T cells, non-T cells and unique antigen presenting cells. Many laboratories, as well as ours, have described the role of intestinal epithelial cells (IECs) as non-professional antigen presenting cells ([@R1]--[@R7]). CD8^+^ regulatory T (Treg) cells can be activated by IECs through the complex formed by the non-classical I molecule, CD1d, and gp180 on IECs. Moreover, we have recently demonstrated that CD8^+^ T cell lines derived from lamina propria lymphocytes of Crohn's disease patients are defective in their suppressive activity. In this scenario, the addition of IEC produced IL-15 or IL-7 cytokines was critical to establish and especially to sustain long-term CD8^+^ T cell cultures ([@R8]). We have characterized gp180 as a surface glycoprotein recognized by two anti-epithelial cell mAbs, B9 and L12. Affinity purified gp180 has been shown to bind to CD1d and CD8α, and to increase CD8-associated Lck kinase activity. Subsequently, CD1d becomes more class I-like molecule, with enhanced CD1d binding to the T cell receptor and gp180 binding to CD8α. In IEC:T cell co-culture experiments, mAbs B9 and L12 block the selective proliferation of CD8^+^ T cells and inhibit the ability of IECs to phosphorylate and activate Lck ([@R9]--[@R19]). Furthermore, using mAb B9 we have demonstrated that gp180 expression was significantly decreased in non-inflamed tissues derived from inflammatory bowel disease (IBD) patients. This defect correlated with the inability of IBD IECs to activate CD8^+^ Treg cells ([@R20]).

The carcinoembryonic antigen family (CEA) belongs to the immunoglobulin gene superfamily consisting of the CEACAM subgroup and the pregnancy specific glycoprotein (PSG). While PSG is secreted, CEACAM subfamily proteins are heavily glycosylated cell surface proteins. They are either transmembrane or glycophosphatidyl-inositol (GPI)-linked. Analysis of amino acid sequences reveals a distinct domain organization amongst the family members. Two types of immunoglobulin (Ig) domains are observed in CEA family members: an N-terminal domain that is homologous to the Ig variable domain (IgV-like) and zero to six C-terminal domains that are homologous to the Ig constant domain (IgC-like). The IgC-like domain may be either of type A or B. CEA is expressed in columnar IECs and goblet cells of the colon, in mucous neck cells and pyloric mucous cells of the stomach, in squamous epithelial cells of the tongue, esophagus and cervix and in the pancreatic duct. Various reports have described a role for CEA family members in cell-cell adhesion engaging homotypic and heterotypic interactions through their N-terminal domains. Several members have been described to act as pathogen sensors suggesting a possible role of CEA in host-pathogen crosstalk. ([@R21]--[@R31]).

We now report that affinity-purified gp180 shows sequence homology with the N-terminal domain of CEACAM5 and we demonstrate that both gp180 and CEACAM5 share common binding and functional properties. We further unravel that CEACAM5 possesses a highly specific positive immunoregulatory function compared to the other four CEACAM family members expressed on IECs. Finally, we delineate a unique set of interactions between CEACAM5/CD1d and CEACAM5/CD8, and for the first time we provide evidence that CEACAM5 give rise to CD8^+^ T cells with potent suppressor functions.

RESULTS {#S2}
=======

CEACAM5 shares homology with gp180 and is recognized by B9 mAb {#S3}
--------------------------------------------------------------

To determine the specific target protein of the mAb B9, gp180 was purified by immuno-affinity using mAb B9 and subjected to amino terminal sequencing by Edman degradation. The first 25 amino acids showed 100% sequence homology with CEACAM5 ([Figure 1a](#F1){ref-type="fig"}). Other CEACAM family members did not exhibit similarities with the obtained gp180 sequence (data not shown). The congruence between the molecular weights and the N-terminal amino acid sequences of gp180 and CEACAM5 strongly supports the contention that these proteins are identical.

Given the N-terminal sequence homology to CEACAM5, we questioned whether this member of the CEACAM family expressed the epitope recognized by mAb B9. We overexpressed CEACAM5 in 293T and FO-1 cells and assessed protein expression by Western blotting. HT29 cells were used as positive control as these cells express endogenous CEACAM5. Our results clearly show that CEACAM5 is recognized by B9 and Col-1 (anti-CEA that recognizes A and B domain) mAbs ([Figure 1b](#F1){ref-type="fig"}).

Identification of the B9 epitopes on CEACAM5 {#S4}
--------------------------------------------

Alignment of CEACAM5 with CEACAM1 or CEACAM6 shows diversity in the amino-acid sequence within the region between residues 42 and 46 of the N-domain. Therefore we generated mutants of CEACAM5 carrying a deletion of this region (N^42^RQII) or a single point mutation in the vicinity of this region (K^35^A) to determine the epitope of CEACAM5 recognized by B9. Flow cytometry analysis of CEACAM5 expressing CHO cells revealed that a large percentage of cells positive for T84.66, a mAb that recognizes the A and B domains of CEACAM5, were also positive for B9. While the mutant K^35^A did not affect the reactivity of B9 with the cells, N^42^RQII strongly reduced B9 staining ([Figure 2a](#F2){ref-type="fig"}). Interestingly, expression of the N70,81A mutant of CEACAM5, which prevents N-domain glycosylation, appears to significantly decrease B9 staining, confirming our previous data that treatment of gp180 with N-glycanase results in loss of the epitope recognized by mAb B9 ([@R9]) ([Figure 2a](#F2){ref-type="fig"}).

B9 mAb recognizes other CEACAM family members {#S5}
---------------------------------------------

To further evaluate the binding between CEACAM5 and B9 mAb, CHO cells overexpressing the four different CEACAM family members (CEACAM1-4L, 5, 6 and 8) were incubated with mAbs B9 and B18 (anti-CEA that recognizes epitopes in the C-terminal domain), and analyzed by flow cytometry. Indeed, CEACAM5 bound to B9 mAb in CHO cells confirming their interaction ([Figure 2b](#F2){ref-type="fig"}). These data suggest that CEACAM5 harbors a domain that is similar or identical to the B9 epitope. Moreover, B9 mAb recognized CEACAM6, CEACAM1-4L, and CEACAM8 but not a non-transfected CHO cell line ([Figure 2b](#F2){ref-type="fig"}). Thus, several CEACAM family members share a common domain similar to the B9 epitope in their N-terminal region and would conceivably have the immunosuppressive function of CEACAM5.

CEACAM5 binds to CD1d through the B3 domain {#S6}
-------------------------------------------

To assess which member of the CEACAM family has binding properties to CD1d, we co-expressed different CEACAMs and CD1d in 293T cells and performed co-immunoprecipitation experiments using the anti-CD1d antibody D5. Our results demonstrate that only CEACAM5 but not CEACAM1 or CEACAM6 interact with CD1d revealed by Western analysis using B9 mAb ([Figure 3a](#F3){ref-type="fig"} and [Supplementary Figure S1a](#SD1){ref-type="supplementary-material"}). To ascertain the CEACAM5/CD1d binding, we additionally performed the reverse co-immunoprecipitation experiments using the B9 mAb. The data illustrated in [Figures 3b](#F3){ref-type="fig"} and [Supplementary Figure S1b](#SD1){ref-type="supplementary-material"} confirms that only CEACAM5 interacts with CD1d. All CEACAM family members contain an extracellular N-terminal IgV-like and various C-terminal IgC-like domains that are designated as type A or B domains. By comparing the sequences of CEACAM1, 5, and 6, we found limited homology within the CEACAM family members in the A2 and B3 (B1 for CEACAM1 and CEACAM6) domains. To further characterize which domain of CEACAM5 is involved in the interaction with CD1d, we generated different deletion mutants of CEACAM5 ([Figure 4a](#F4){ref-type="fig"}) and performed co-immunoprecipitation experiments as described above. Neither deletion of the N-terminal region nor of the A2 domain contributes to the interaction between CEACAM5 and CD1d ([Figure 4b](#F4){ref-type="fig"}). In contrast, sequential C-terminal truncations of each domain allowed us to determine that deletion of the B3-domain obliterated the ability of CEACAM5 to bind to CD1d ([Figure 4c](#F4){ref-type="fig"} and [Supplementary Figure S2](#SD1){ref-type="supplementary-material"}). We then performed sequential deletions within the B3 domain and we found that the interaction between CD1d and CEACAM5 depends upon the integrity of fragments 2 to 5 of the B3 domain. Deletion of this region completely abrogated the CEACAM5-CD1d binding ([Figure 4c](#F4){ref-type="fig"} and [Supplementary Figure S2](#SD1){ref-type="supplementary-material"}).

CEACAM5 binds to CD8α chains and induces the phosphorylation of CD8-associated kinase Lck {#S7}
-----------------------------------------------------------------------------------------

CEACAM5 exists as a GPI-anchored glycoprotein on the surface of IECs. The molecule can therefore be removed by cleaving the anchor with the enzyme Phosphoinositide phospholipase C (PIPLC) as previously described ([@R9]). CEACAM5 released from transfected 293T cells by PIPLC treatment was used in a series of absorption studies. First, we assessed by Western blotting the levels of CEACAM5 in the supernatants of 293T cells transfected with CEACAM5 or empty control vector and treated with PIPLC (Sup1). HT29 cells were used as positive control. Next, melanoma cell line FO-1 as well as murine hybridoma T cells expressing either human CD4 (3G4) or human CD8α (3G8) were co-cultured with Sup1 and the amount of remaining CEACAM5 was evaluated in the supernatants (Sup2) using Col-1 antibody. This will be indicative of how much CEACAM5 was absorbed by CD4 or CD8α expressed on the T cells. Our results show that CEACAM5 levels in Sup2 were decreased when incubated with 3G8 cells suggesting that CEACAM5 present in Sup1 was absorbed by CD8α on these T cells ([Figure 5a](#F5){ref-type="fig"}).

Furthermore, we performed similar experiments using human IEC T84 cells that express several CEACAMs on their surface. Absorption of CEACAM5 from the Sup1 by either CD4 or CD8α was determined by immunoblotting using B9 and Col-1 antibodies. Human CD8α but not CD4 expressing hybridoma cells were capable of absorbing the B9 reactive material ([Figure 5b](#F5){ref-type="fig"}). Interestingly, these findings are consistent with functional properties previously ascribed to gp180. To determine whether binding to CD8α had functional significance, we evaluated CEACAM5′s ability to induce the phosphorylation of CD8-associated kinase Lck. Using Western blot analysis, we observed an increase in p-Lck levels 15 min after treatment of 3G8 cells with purified CEACAM5 ([Figure 5c](#F5){ref-type="fig"} and [Supplementary Figure S3a](#SD1){ref-type="supplementary-material"}). We further validated the activation of Lck by flow cytometry analysis in freshly isolated human peripheral blood CD8^+^ T cells. Phosphorylation of Lck occurred in a time dependent manner following treatment of CD8^+^ T cells with purified CEACAM5 peptide, OKT8 (anti-CD8 mAb) or Sup1 from T84 cells with PIPLC ([Figure 5d](#F5){ref-type="fig"}). In contrary, CD4^+^ T cells stimulated with purified CEACAM5 or OKT8 did not show any increase in LcK phosphorylation. Moreover, we evaluated whether CEACAM5 induces phosphorylation of ZAP70, a CD3 ζ-chain-associated protein kinase. Similar to LcK activation, purified CEACAM5 induced phosphorylation of ZAP70 in a time dependent manner ([Supplementary Figure S3b-c](#SD1){ref-type="supplementary-material"}). These data suggest that CEACAM5 not only specifically binds to CD8α but similarly to gp180 induces phosphorylation and activation of CD8-associated Lck.

CEACAM5-CD8α interaction is dependent on a specific glycosylation site within the N-domain {#S8}
------------------------------------------------------------------------------------------

To define the binding affinity between wild type CEACAM5 and CD8α, we used the Biacore system, where one molecule (soluble ligand CD8α or control CD4) is immobilized on a dextran matrix and the putative analyte in solution (CEACAM5 wild type or mutants) is passed over the surface ([Figure 6a](#F6){ref-type="fig"} and [Supplementary Figure S4](#SD1){ref-type="supplementary-material"}). A full kinetic analysis of wild type CEACAM5/CD8α binding revealed that the affinity was equivalent to the interaction affinity between CD8α and MHC I ([Figure 6b](#F6){ref-type="fig"}) ([@R32], [@R33]). The derived affinity constant was evaluated to be 2.20E-08 M and calculated using the following on-rate and off-rate constants, 2.60E+04 M-1s-1 (K~ON~) and 5.60E-04 s-1 (K~OFF~), respectively ([Figure 6d](#F6){ref-type="fig"}). Binding of CEACAM5 to CD8α was observed with as low as 50 nM of purified CEACAM5 protein. No binding was detected between wild type CEACAM5 and recombinant CD4 protein ([Figure 6c](#F6){ref-type="fig"}). To assess whether deletion of N42 to I46 residues in the N-terminal domain of CEACAM5 affected the binding affinity, we next studied the interaction between N^42^RQII and CD8α. Biacore analysis showed a significant and similar reduction in the K~D~ of N^42^RQII when compared to wild-type CEACAM5 binding to CD8α (K~D~=1.70E-08 M; K~ON~=9E+04 M-1s-1; K~OFF~=1.5E-03 s-1) ([Figure 6d](#F6){ref-type="fig"}). Subsequently, we evaluated the interaction affinity between the different CEACAM5 mutants to CD8α. Interestingly, the affinity of the mutant N70,81A CEACAM5 to CD8α binding (K~D~=1.60E-05 M; K~ON~=2.90E+02 M-1s-1) and K~OFF~=4.70E-03 s-1) appeared to be very low when compared to the wild type CEACAM5, whereas the K35A mutant had comparable K~D~ value to N^42^RQII and wild-type CEACAM5 (K~D~=1.50E-07 M; K~ON~=1.50E+04 M-1s-1 and K~OFF~=2.30E-03 s-1) ([Figure 6d](#F6){ref-type="fig"}). These results suggest that the loss of the initial glycosylation of CEACAM5 highly affects its conformational structure resulting in a reduction in affinity between CEACAM5 and CD8α.

Furthermore we performed Western blot analysis using N70,81A CEACAM5 mutants and revealed a decrease in phosphorylation compared with wild type CEACAM5 ([Figure 5](#F5){ref-type="fig"}). To demonstrate that there is a partial overlapping binding site on CEACAM5 for both B9 mAb and CD8α, we performed a competition assay by premixing CEACAM5 peptide with B9 mAb and consecutively adding the mixture to CD8α on the chip. As expected, no binding was observed suggesting that the B9 mAb blocks CEACAM5/CD8α interactions ([Supplementary Figure S5](#SD1){ref-type="supplementary-material"}).

CEACAM5-activated CD8^+^ T cells acquire suppressive functions {#S9}
--------------------------------------------------------------

IECs have been described to activate peripheral CD8^+^ T cells, which become potent suppressor cells ([@R12]). Moreover lamina propria CD8^+^ T cells from Crohn's disease patients have shown a reduced suppressor activity when compared to healthy controls ([@R8]). To study the function of CEACAM5-activated peripheral CD8^+^ T cells, we first cultured freshly isolated human CD8^+^ T cells in the presence of CEACAM5 alone or in combination with IL-15 or IL-7. Previous studies using various cytokine combinations have shown that IL-7 and/or IL-15 are critically important for the development of long-term lines in IEC:T cell co-cultures ([@R8]). First, we assessed the expression of granzyme B in CD8^+^ T cells cultured for 72 h in the presence of CEACAM5. Granzyme B was not detectable in these conditions suggesting that CD8^+^ T cells activated by CEACAM5 are not cytotoxic T cells (data not shown). Next, we performed suppression assays by assessing the ability of the stimulated CD8^+^ T cells to suppress proliferation of CD4^+^ T cells. As shown in [Figure 7](#F7){ref-type="fig"}, CD8^+^ T cells pre-incubated with CEACAM5 along with IL-15 strongly suppressed the proliferation of CD4^+^ T cells to the same extent as CD8^+^ T cells treated with anti-CD3/CD28 antibodies. Combination of CEACAM5 and IL-7 resulted in a similar but lower CD4^+^ T cell suppression when compared to CD8^+^ T cells pre-incubated with IL-15 ([Supplementary Figure S6](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#S10}
==========

Our previous studies have focused on a novel role for IECs as antigen presenting cells. We have defined that IECs can take up soluble antigens and present them to T cells. In the normal state, such presentation results in the selective activation of CD8^+^ suppressor T cells. We have characterized this interaction by identifying two molecules expressed by normal IECs that bind to the T cell receptor (TCR) and to CD8 molecules on these regulatory T cells, CD1d and gp180, respectively. We have also generated a monoclonal antibody that specifically recognizes gp180. We have determined that this mAb was epithelial cell specific; it inhibited IEC induced CD8^+^ T cell proliferation and blocked the activation of CD8-associated Lck. This approach has lead to the identification of molecules involved in IEC:T cell interactions, specifically CD8^+^ T cells. Purified gp180 was shown to be important in activating Lck through binding to CD8α and CD1d ([@R9]--[@R20]).

CEACAM5 is an oncofetal antigen originally discovered as a cell surface molecule whose tissue and blood levels positively correlated with colorectal cancer. All members of the family have been shown to function, at least *in vitro*, as homotypic and heterotypic intercellular adhesion molecules. Modification in the expression of two GPI-anchored members, CEACAM5 and CEACAM6 have been shown to inhibit differentiation and anoikis, to disrupt cell polarization and tissue architecture, effects that altogether enhance tumorigenesis. Transmembrane anchored CEACAM1, on the other hand, has none of these properties, but possesses tumor suppressive and angiogenic effects. CEACAM1 is evolutionarily conserved, expressed in many adult tissues and mainly participates in the modulation of T cell function to bile acid transport. GPI-anchored CEA family members evolved just prior to the primate radiation and the only functions ascribed to them, other than intercellular adhesion, involve the binding of their sugars to bacteria and to selectins, facilitating binding of neutrophils to vascular endothelium (a property shared by CEACAM1) ([@R21]--[@R31]). More recently, CEACAM6 has been proposed as a receptor for the type 1 pili expressed by adherent-invasive Escherichia coli (AIEC) and its abnormal expression seen in Crohn's disease patients has been correlated to higher colonization and inflammation induced by AIEC ([@R34]). Prior studies from our laboratory have described a regulatory/suppressor CD8^+^ T cell population, CD8^+^CD28^−^CD103^+^ population, which undergoes oligoclonal expansion in the lamina propria of the gut after interacting with an MHC class I-like complex on the basolateral surface of an epithelial cell ([@R35]).

In this study we show that gp180 share homology with CEACAM5. First, we confirmed that CEACAM5 and gp180 have the same amino acid sequence and that B9 mAb is capable of recognizing CEACAM5. We showed that CEACAM5 binds to CD8α and induces Lck phosphorylation. Furthermore, we demonstrated that amongst the CEACAM family members, CEACAM5 is the only one that interacts with CD1d. We confirmed that CEACAM5 interacts with CD1d through the B3-domain and that the sugar bridge between residues 70 and 81, which is the first highly conserved glycosylation site within the N-domain implicated in protein-protein interactions, is crucial for CEACAM5/CD8 binding and CD8 kinase Lck activation ([@R28]). Biacore protein-protein affinity analysis validated that the N70,81A mutant strongly impacts CEACAM5/CD8 binding. Therefore glycosylation of the N-domain of CEACAM5 is crucial for its interactions to CD8α. Moreover, we have proven that B9 mAb and CD8α have affinity to a similar binding site on CEACAM5 by competition experiments. These findings corroborate with previous observations and confirmed that B9 mAb blocks the induction of CD8^+^ regulatory T cells.

Since its identification in 1965 by Gold and Freeman, the functional relevance of CEACAM5 and its homology to other CEA subfamily members in normal tissues has been poorly understood. It has been shown that bacterial binding to epithelial cells might be facilitated by the sugar structures present on CEACAM5 and CEACAM6. Furthermore, the abnormal expression of CEACAM6 in CD patients has been correlated to a higher bacterial colonization and increased inflammation mediated by AIEC bacteria ([@R34]). Here, we showed for the first time a novel biochemical and functional activity mediated by CEACAM5. We have proven that CEACAM5 has the ability to bind to both CD8α and CD1d and hence co-activate CD8^+^ T cells. It is possible that non-classical class-I molecules share similar features, where they complex with an additional molecule to make them more alike classical class-I or class-II molecules. In colon cancer, CEACAM5 and CEACAM6 are dysregulated and over-expressed ([@R24]--[@R25]). It has also been described that CEACAM5 bound by liver Kupffer cells may play a role in enhancing metastasis by stimulating and producing various cytokines ([@R26]). Another CEA subfamily member, CEACAM1, is expressed on both IECs and T cells and has been shown to inhibit the cytolytic activity of intestinal intraepithelial lymphocytes ([@R31]), although activation of NK cells mediated by CEACAM1 has also been reported ([@R30]).

For the first time, our study describes that CEACAM family members present distinct immunoregulatory functions despite their structural similarities. Only CEACAM5 interacts with CD1d. Moreover, CEACAM5 binds to CD1d and CD8α through different domains. Therefore, we believe that there is constant trafficking of CEACAM5 from the membrane compartment to the intracellular compartment. Apically, CEACAM5 could potentially be involved in antigen uptake, while basolaterally it forms a complex with CD1d and acts as an MHC class I molecule. Epithelial antigen processing occurs in a highly polarized fashion, with apical antigens being sorted and presented exclusively basolaterally. We also believe that this unique set of interactions could facilitate antigen presentation by CD1d to T cells and allows the subsequent activation of CD8^+^ regulatory T cells with potent suppressive functions ([Figure 8](#F8){ref-type="fig"}). We previously described that IECs derived from IBD patients have a defect in the expression of CEACAM5 (gp180) due to an evident failure to activate CD8^+^ regulatory T cells ([@R36]). More recently, we generated lamina propria CD8^+^ T suppressor lines in presence of aCD3 monoclonal antibody visilizumab, together with IL-15 and IL-7 and we determined that lamina propria CD8^+^ T suppressor cells from Crohn's disease patients have a reduced suppressor activity. ([@R8]). Interestingly, here we extend these findings and show that CEACAM5-activated CD8^+^ T cells acquire important suppressive functions. Hence, understanding the interactions between CEACAM5/CD1d and CD8α/TCR in the mucosal immune system in normal individuals will allow the development of new approaches to promote induction of suppressive immune responses (in Crohn's disease) or to enhance mucosal immunity (oral vaccines).

METHODS {#S11}
=======

Purification and sequencing of gp180 {#S12}
------------------------------------

gp180 purification from human intestinal epithelial cells (IECs) was performed using a mAb B9 affinity column as described previously ([@R9]). Protein sequencing was accomplished by the Protein DNA Core at the Rockefeller University.

Construction of vectors {#S13}
-----------------------

### Dual expression vector of CEACAMs and CD1d {#S14}

cDNAs for CEACAM1, CEACAM5, CEACAM6 and CD1d (Genbank accession no NM_001024912, NM_004363, NM_002483 and NM_001766) were obtained by RT-PCR from human IEC mRNA. All of the primers are shown in [supplementary Table S1](#SD1){ref-type="supplementary-material"}. An internal ribosomal entry site (IRES) was amplified from the pIRES-EGFP plasmid (Clontech) using forward (5′-CCGAATTCATTCCGCCCCTCTCC-3′) and reverse (5′-CCGGATCCGGGTTGTGGCAAGC) primers. Then the IRES alone (IRES), IRES-CD1d (CD1d), IRES-CEACAM5-GFP as well as IRES-CD1d simultaneously with CEACAM1, CEACAM5 or CEAMCAM6 (CEACAM1.CD1d, CEACAM5.CD1d and CEACAM6.CD1d) were subcloned into pcDNA3.1(−) vector (Invitrogen).

### Vectors expressing mutants of CEACAM5 {#S15}

Wild-type (WT) CEACAM5 construct was used as a template for PCR-generated mutant constructs. For sequential C-terminal truncation, the forward primer for WT was used and the reverse primers for all the deletion mutants including B3, A3B3, B2A3B3, B3.1, B3.2, B3.3, B3.4, B3.5 are shown in [Table S2](#SD1){ref-type="supplementary-material"}. Overlap extension PCR was performed to construct the expression vector for deletion of the A2-domain. The forward primer for the WT CEACAM5 and reverse primer (5′-GACGACCCCACCATTTCCCCCTCA-3′) were used to generate fragment 1. The forward primer (5′-GGTGGGGTCGTCGGGTGGCTCTGCATA-3′) and reverse primer for WT CEACAM5 were used to generate fragment 2. Then the cDNA with the deletion of A2-domain was generated from fragment 1 and 2 using primers for WT. The PCR fragments were subcloned into CD1d-pcDNA3.1(−). The p91023(B) vectors encoding WT and mutant CEACAM5 with deletion of N42 to I46 residues in the N-terminal domain (N^42^RQII), point mutations in the N-terminal domain (K35A and N70,81A) and CEACAM8 were generated. The sequences of all constructs were confirmed by DNA sequencing. CD8α cDNA was provided by Dr P. Kavathas (Yale School of Medicine) and the extracellular domain was sub-cloned into a pcDNA 3.1/V5-His vector.

Cell culture and transfection {#S16}
-----------------------------

For transfection, a human embryonic kidney (293T), an ovarian Chinese hamster carcinoma (CHO) and a melanoma (FO-1) cell lines were used. The cells were grown at 37°C in Dulbecco's modified Eagle's medium (GIBCO, Carlsbad, CA) or in F-12K medium (ATCC) containing 10% fetal bovine serum (FBS), in a humidified 5% CO~2~ incubator. Cells were transfected in 6-well plates using Lipofectamine-2000 (Invitrogen) with 4 μg of pcDNA3.1 vectors encoding CD1d alone or along with wild-type or truncated CEACAM5. Untransfected or cells transfected with IRES were used as controls. For the generation of stable cells expressing wild-type and mutant CEACAM5, cells were transfected in 100 mm culture plates with 12 μg of p91023(B) expression vectors encoding wild-type or mutant CEACAM5 together with 12 μg of pcDNA3.1. The stable cells were established after selection with 3 mg/ml Geneticin (G418, Sigma). Stable cells were treated with 0.1unit/ml phospholipase C, phosphatidylinositol specific enzyme (PIPLC, Sigma) for 1 h at 37°C. The supernatant was collected and subjected to Western blotting using mouse Col-1 and mouse anti-gp180 (B9) monoclonal antibodies. Human IEC cell lines, HT29 and T84, were used as positive controls.

Western Blots {#S17}
-------------

The protein samples were subjected to 10% SDS-PAGE gels, transferred to nitrocellulose membranes and blocked with 5% milk for 1 h at room temperature. Membranes were incubated with primary antibodies overnight at 4°C, washed with (phosphate buffered saline) PBS containing 0.05% Tween-20, and incubated with HRP-conjugated secondary antibody (Cell Signaling) for 1 h at room temperature. The proteins were visualized using a chemiluminescent HRP substrate (Millipore).

In-Cell Western Blot {#S18}
--------------------

200×10^4^ CD8^+^ T cells were seeded in a 96 well flat-bottom plate and starved in RPMI serum free medium overnight at 37°C. The next day and prior to perform the experiments, the plate was placed on ice for 15 min. Cells were stimulated with OKT8 (5μg/mL) or purified CEACAM5 peptide (10μg/mL). Unstimulated cells were obtained for each condition. Stimulation was stopped using a 4% formaldehyde buffer for 20 min followed by centrifugation for 10 min at 1,500 rpm. Permeabilization was performed by washing the cells with 1x PBS containing 0.1% Triton X-100 for 5 min per wash. After permeabilization, cells were incubated for 1 h with the blocking buffer (Odyssey Blocking buffer-LICOR) followed by the primary antibodies goat anti-actin and rabbit anti pLcK or pZap70 overnight at 4°C. The next day, cells were washed 5 times with 1x PBS containing 0.1% Tween 20, incubated for 1 h at room temperature with the secondary antibodies (IRDye 800CW donkey anti goat IgG, IRDye 680 CW donkey anti rabbit IgG) and than washed for five times. Wells were dried and the plate was scanned using an Odyssey LiCOR system. The software ImageStudio was used for quantification and each well was corrected taking into consideration the actin expression and the background noise.

Flow cytometry {#S19}
--------------

Trypsinized CHO cells (1×10^6^) expressing CEACAM5, 1, 6 and 8 were incubated with the appropriate mAbs B9 and B18 diluted in 100 μL PBS containing 0.2% FBS and followed by a second incubation on ice with FITC-labeled F(ab)′~2~ fragments of immunosorbent-purified goat anti-mouse IgG.

CEACAM5 mutants transfected CHO cells (1×10^6^) were incubated with the appropriately diluted mAb T84.66 antibody in 100 μL of phosphate buffer solution (PBS) containing 0.2% fetal bovine serum followed by phycoerythrin-labeled F(ab)′~2~ fragments of immunosorbent-purified goat anti-mouse IgG. Subsequently cells were washed and co-stained with mAb B9 in 100 μL of phosphate buffer solution (PBS) containing 0.2% fetal bovine serum followed by FITC-labeled F(ab)′~2~ fragments of immunosorbent-purified goat anti-mouse IgG. Incubations were performed on ice. The cells were then suspended in PBS plus 0.2% FBS and analyzed on a FACScan.

CD8^+^ T and CD4^+^ T cells were treated for different time points (2, 8, 10, 15 min) at 37°C with anti-CD8 mAb (OKT8) at 5 μg/L, H~2~O~2~ at 10 mM, CEACAM5 supernatant (Sup1) from PIPLC-293Tcells expressing CECACAM5 and purified CEACAM5 peptide at 20μg/mL. Stimulation was stopped by fixing with 4% formaldehyde for 10 min at room temperature. Subsequently, cells were permeabilized with ice-cold methanol for 20 min, washed with PBS containing 0.2% FBS and stained with anti-phospho-Lck Ab (BD Bioscences). The cells were then re-suspended in PBS plus 0.2% FBS, data acquired using the FACScan system and data analyzed with FlowJo analysis software.

Co-immunoprecipitation {#S20}
----------------------

293T cells were used for co-immunoprecipitation 48h after transfection with the corresponding vectors as described above. Cell extracts (150 μg of protein) were incubated with either 2 μg of mouse IgG2b anti-CD1d (D5), mouse IgG1 anti-gp180 (B9), isotype control mouse IgG2b or mouse IgG1 for 4h at 4°C, followed by the addition of 10 μl protein G Sepharose (Amersham Biosciences) for 12h. Pellets were washed three times with RIPA buffer (10 mM Tris, pH 8.0, 1.0 mM EDTA, 0.5% Nonidet P-40, 0.1 M NaCl), boiled in SDS sample buffer, and resolved on SDS-PAGE gels. After transferring to nitrocellulose, an anti-CEA mAb (Col-1) (Dako) followed by a CD1d mAb D5 Western blot was performed.

Absorption assay {#S21}
----------------

10 μL of PIPLC treated supernatants from 293T/CEACAM5 cells or from confluent T84 cells were incubated on ice with 14 x 10^6^ 3G4 (mouse T cell hybridoma transfected with human CD4 cDNA) or 3G8 (mouse T cell hybridoma transfected with human CD8 cDNA) cells for 1 hour. After incubation, 20 μL of RPMI were added to each tube to facilitate collection of the absorbed supernatants. Supernatants (Sup2) were collected following centrifugation at 13,000 rpm for 2 minutes. The entire 30 μL was resolved in 8% SDS-PAGE and subjected to Western Blot analysis.

Protein purification {#S22}
--------------------

The supernatant obtained from treated PIPLC transfected CHO cell lines was collected and subjected to mouse anti-CEA (Col-1) mAb Western blot. Supernatants expressing CEA were subjected to a Col-1 Ab (A/B domain specific) purification column, to dialysis using dialysis membrane tubing with MWCO of 12000--14000 and to concentration using Vivaspin 6 columns. Supernatant obtained from CD8α transfected 293T cells containing the extracellular domain of CD8α was collected and subjected to a mouse monoclonal anti-CD8α Antibody Western Blot. Supernatant expressing CD8α was purified using the Probond purification System-Invitrogen specific for polyhistidine-containing recombinant proteins. Eluted protein was then subjected to dialysis and concentration. Eluted proteins were finally subjected to mAb Col-1 (Zymed) and mAb CD8α Western Blot (Santa Cruz) to confirm the presence of full length and mutants CEACAM5s and CD8α.

Biacore Kinetic Analyses {#S23}
------------------------

As assay buffer, we used 10 mM HEPES buffer (pH 7.4), 150 mM NaCl, 3mM EDTA, 0.005% P20 (polyoxyethylenesorbitan); as regeneration buffer we used 50mM Tris, 2M NaCl, pH 7.3 and as conjugation buffer we used 10 mM sodium acetate buffer (pH 5.0). Purified CD8α protein was directly immobilized to the high capacity carboxymethylated dextran and covalently attached to a gold surface (CM5 chip) by amine coupling chemistry. The amount (R~L~) of protein to be captured on the chip was determined by the following formula: R~Max~=MW~A~/MW~L~ • R~L~ where MW~A~ is the molecular weight of the analyte (CEACAM5) (180 KDa) and MW~L~ is the molecular weight of the ligand (CD8α) (19 KDa). R~Max~ corresponds to the maximum resonance unit that we obtained during analyses. We set R~Max~ below 50 for antibody/antigen interactions. R~L~ corresponds to the refractory index of the ligand and is expressed in resonance units (RU). R~MAX~ of 50 was R~L~ = 50 x 19/180 = 5.3. We captured the ligand onto the chip until it reached 5.3 RU. RU is a Resonance Unit generated by the shift of refractory index due to ligand-analyte interactions on a sensor chip. KD is defined as KD = Kd/Ka.

Biacore measures real time Ka (on rate) and Kd (off rate) based on its curve fitting program. The flow rate used for capturing ligand is 5 ml/min. For kinetic analysis, the flow rate of 30 ml/min is used for the analyte. The first run is the scouting analysis using high concentrations of analyte. For the assays we used 200 nM. At this concentration, binding should be observed even if the ligand binding affinity is weak. The scouting analysis provides a rough K~D~. Based on the rough K~D~ value, full kinetics analyses are performed using 5 analyte concentrations slightly above the K~D~ to zero. Chi square (χ^2^) analysis on the K~D~ values obtained from each analyte concentration was performed to determine the statistical accuracy of the measured K~D~. χ^2^ value of \~2 is considered significant (accurate) and below 1 is highly significant (highly accurate). After each assay, the chip is treated with 50mM Tris, 2M NaCl, pH 7.3 to remove the ligand and the analyte for regeneration.

*In vitro* suppression assay {#S24}
----------------------------

To evaluate the effect of CEACAM5-activated CD8^+^ T cells on anti-CD3/CD28 antibody stimulated peripheral CD4^+^ T cells. CD8^+^ T cells and CD4^+^ T cells were positively selected using respectively a CD8^+^ and CD4^+^ T-cell selection kits (Stemcell Technologies, Vancouver, Canada). CD8^+^ T cells were incubated for 3 days in the presence or absence of purified CEACAM5 or OKT8 in combination with IL15 or IL7. Anti-CD3/CD28 beads were used as positive controls. Purified CEACAM5 and OKT8 were added every day for 3 days. Then, cells were washed, counted and added at a ratio of 1:1 to peripheral CD4^+^ T cells labeled with carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen, CA) and either unstimulated or stimulated with anti-CD3/CD28 beads. Proliferation of CD4^+^ T cells measured by CFSE dilution was analyzed by flow cytometry.

Supplementary Material {#S28}
======================

This work was supported by NIH grants AI044236, AI084952, DK072201, DK086605 and a grant from the CCFA.

All authors have nothing to disclose.

[Supplementary Material](#SD1){ref-type="supplementary-material"} is linked to the online version of the paper at <http://www.nature.com/mi>

**DISCLOSURE**

The authors declare no conflict of interest.

![CEACAM5 share homology with gp180 and is recognized by B9 mAb\
(**a**) Amino-terminal sequence of the specific target protein of the mAb B9, gp180 and CEACAM5. The first 25 amino acids showed 100% sequence homology with CEACAM5. (**b**) Immunoblotting for CEACAM5 in lysates obtained from HT29, as well as FO-1 and 293T cells transfected with CEACAM5. B9 and Col-1 monoclonal antibodies were used for Western blotting. Non-transfected FO-1 and 293T cells were used as negative control. Data are representative of three independent experiments.](nihms523434f1){#F1}

![B9 recognizes different CEACAMs expressed on IECs but specifically binds to a unique region in the N-domain of CEACAM5\
(**a**) Cytofluorimetric profiles of CHO cells transfected with wild type CEACAM5, a N^42^RQII deletion mutant, and point mutants K35A, and N70,81A and double-stained with mAb T84.66 and mAb B9. B9 reactivity was reduced with cells expressing the deletion mutant and the sugarless mutant of CEACAM5. (**b**) Cyto-fluorimetric profiles of CHO cells expressing CEACAM5 or CEACAM1-4L, CEACAM6 and CEACAM8, labeled with B9 or B18 mAbs. B9 can recognize all four CEACAM members. Data are representative of three independent experiments.](nihms523434f2){#F2}

![CEACAM5, but not CEACAM1 or CEACAM6 binds to CD1d\
293T cells were co-transfected with pcDNA3.1-IRES-CD1d alone or together with CEACAM1, CEACAM5 or CEACAM6. The cell lysate was co-immunoprecipitated with mouse IgG2b anti-CD1d (D5), or with mouse IgG1 anti-gp180 (B9) antibodies. Western blots were performed with Col-1 and D5 mAbs. Data are representative of three independent experiments.](nihms523434f3){#F3}

![The B3 domain of CEACAM5 is involved in its interaction with CD1d\
293T cells were transfected with expression vectors pCDNA3.1-IRES expressing CD1d and wild-type or truncated CEACAM5. The cell lysate of the transfectants was immunoprecipitated with mouse IgG2b anti-CD1d (D5). Western blot was then performed with Col-1 and D5 mAbs. **(a)** Schematic rapresantation of deletions of the N-domain, A2 domain and C-terminal truncations (**b)** WT and CEACAM5 with the deletion of N-domain (N) co-immunoprecipitate with CD1d. WT and CEACAM5 with the deletion of A2-domain (A2) co-immunoprecipitate with CD1d. (**c**) CEACAM5 with the sequential C-terminal truncations of each domain fails to co-immunoprecipitate with CD1d. CEACAM5 with the deletion of fragment 1 of B3-domain co-immunoprecipitates with CD1d. With further deletion of the B3 domain, CEACAM5 fails to co-immunoprecipitate with CD1d. Data are representative of three independent experiments.](nihms523434f4){#F4}

![CEACAM5 binds CD8α and induces phosphorlylation of CD8-associated LcK\
(**a**) 3G4 and 3G8 cells were incubated with PIPLC supernatants from CEACAM5 transfectants, vector control 293 T cells, or (**b)** IECs cell line T84. FO-1 cells were used as negative control. Absorbed or unabsorbed supernatants were subjected for immunoblotting using Col-1 or B9 mAbs. 3G8 but not 3G4 were capable of absorbing CEACAM5. Data are representative of three independent experiments. (**c**) 3G cells were incubated with purified CEACAM5 for different time points and subjected to immunoblotting for anti-phosphoLcK mAb. At 15′ CEACAM5 induce phosphorylation of LcK. Data are representative of three independent experiments. (**d)** Flow cytometry analysis of p-Lck staining in human peripheral CD8^+^ T cells and CD4^+^ T cells stimulated with Sup1, mAb CD8 and CEACAM5 purified peptide for different time points. H~2~O~2~ represents the positive control. Data are representative of five independent experiments.](nihms523434f5){#F5}

![Removal of N-domain sugar bridge reduces CEACAM5-CD8α binding affinity\
(**a)** Schematic representation of CEACAM5 N-domain mutants. **(b)** Binding of soluble wild type CEACAM5 (WT) to immobilized CD8**α** peptide and (**c**) of wild type CEACAM5 to immobilized recombinant CD4 peptide. (**d)** KD values of binding of wild Type CEACAM5, N^42^RQII, K35A and N70,81A to immobilized CD8α peptide.](nihms523434f6){#F6}

![Suppressor activity of CEACAM5-activated CD8^+^ T cells\
Proliferation of CFSE labeled CD4^+^ T cells in the presence of anti-CD3/CD28 beads, CD8^+^ T cells, anti-CD3/CD28 stimulated CD8^+^ T cells, CEACAM5 +/− IL15 stimulated CD8^+^ T cells, and OKT8 +/− IL15 stimulated CD8^+^ T cells. Data are representative of four independent experiments.](nihms523434f7){#F7}

![Interactions between CEACAM5/CD1d and CEACAM5/CD8α\
Intestinal epithelial cells express CEACAM5 and CD1d on their surface. CEACAM5 (gp180) interacts with CD1d through the B3 domain. Fragment 1 of the B3 domain is not required for its interaction with CEACAM5. The sugar bridge in the N domain of CEACAM5 is crucial for it's binding to CD8α and for the activation of CD8-associated LcK. CEACAM5-activated CD8^+^ T cells acquire suppressive functions and reduce the proliferation of CD4^+^ T cells.](nihms523434f8){#F8}
